Quest Diagnostics
NYSE: DGX
Stock price
230.81 USD
(+62.62%) 5 years
Financial Performance
5Y price score: 81
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 201%
%
ㅤ
By default your notes are visible only to you.
171.1
52-week range
248.8
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
4.7 %
Dividend Yield TTM
1.5 %
Market cap $
$ 25,475
Price / Earnings TTM
24.5
Price / Book TTM
3.4
PEG TTM
1.8
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
29.3 %
72.9 %
201 %
Free cash flow per share growth
(23.6) %
3.1 %
218.8 %
Earnings per share growth
15 %
(16.8) %
79.7 %
Founded: 1,967
Employees: 55,000
Business Summary:
Q&A
Contribute
By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more
Latest Earnings Call Takeaways
2026 Q2 (Jul 23, 2026)
1) Strategic Execution and Leadership Changes - Quest Diagnostics continues to focus on connecting people and providers through innovative testing and actionable insights. - The company welcomed Domini Chokshi as the new Head of Investor Relations, bringing extensive experience from Merck. - Leadership emphasized the importance of automation and AI in improving quality and productivity across operations.
2) Financial Performance and Segment Results - Consolidated revenues for Q2 2026 were $3.04 billion, up 10.2% YoY, with organic revenue growth at 10%. - Adjusted diluted EPS increased by over 19% to $3.12, driven by strong organic performance and a favorable tax resolution. - Diagnostic Information Services revenue rose by 10.3%, with significant contributions from physician, hospital, and consumer channels. - Volume growth was robust, with requisitions up 13.1% YoY, largely due to collaborations with Corewell Health and Fresenius Medical Care.
3) Operational Excellence and Innovations - The company is on track to achieve 3% annual cost savings through its Invigorate program. - Investments in AI and automation are enhancing operational efficiency, including the installation of advanced diagnostic systems in labs. - New tools like IntelliDraw are improving specimen collection processes for clinical staff, aiming to enhance service quality.
4) Challenges and Market Headwinds - The company anticipates a 30 basis point revenue impact from ACA changes, although current business performance remains stable. - Pricing pressures persist in the competitive lab testing market, with overall pricing expected to remain flat. - The impact of rising fuel costs and increased Nova expenses are noted as potential headwinds for the second half of the year.
5) Guidance and Outlook - Quest Diagnostics raised its full-year revenue guidance to a range of $11.95 billion to $12.05 billion, reflecting an 8.3% to 9.2% growth rate. - Adjusted EPS guidance is now set between $11.05 and $11.25. - The company remains optimistic about continued strong demand across its customer channels and plans to leverage its innovations for growth.
Bottom line: Quest Diagnostics is demonstrating strong financial performance and strategic execution, with robust growth across its segments. The company is well-positioned to navigate headwinds while continuing to innovate and expand its services, making it an attractive proposition for shareholders.
Annual Reports, Presentations And IR Contacts
Go to the websiteQuest Diagnostics — Financial Overview, Stock Price, Market Cap
Quest Diagnostics is a company. Founded in 1967. As of October 9, 2026, the company's market capitalization is $25475192130 with a current stock price of $230.81.